AzTrials
AzTrials

Postoperative Sleep DisturbancesPhase 4NCT06898463

Comparison Of The Effects Of Melatonin Premedication And Ketamine On Postoperative Sleep Quality İn Rhinoplasty

A Phase 4 study testing Melatonin (N-acetyl-5-methoxytryptamine) and Ketamine in people with Postoperative Sleep Disturbances, run by Konya City Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background Postoperative sleep disorders are common complications of surgery and anesthesia that prolong morbidity and hospital stay. Various methods are being explored to prevent and treat these issues. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Postoperative Sleep Disturbances
What is being tested?
Melatonin (N-acetyl-5-methoxytryptamine) and Ketamine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
183 participants
Where
1 siteTurkey (Türkiye)
Study dates
19 Sep 2022to 25 Dec 2024
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients capable of providing consent
  • Patients able to reliably report their symptoms to the research team
  • Patients with American Society of Anesthesiologists (ASA) physical status I-II
  • Patients aged 18-65 years
  • Patients undergoing rhinoplasty surgery

Who cannot join

  • Patients with cognitive impairment or a communication barrier
  • Patients with a BMI > 30
  • Patients with OSAS (Obstructive Sleep Apnea Syndrome)
  • Patients with a known psychiatric disorder
  • Patients with renal failure
  • Patients with liver failure
Show all 12Show fewer
  • Patients with cardiovascular disease (e.g., heart failure, coronary artery disease, arrhythmia, etc.)
  • Patients with malignancy
  • Patients who are pregnant or lactating
  • Patients with a history of allergy to melatonin and ketamine
  • Patients with an American Society of Anesthesiologists (ASA) Physical Status score ≥3
  • Patients who do not consent to participate in the study

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Necmettin Erbakan University Faculty of Medicine

    Konya, Selçuklu, 42080

Other trials in Turkey (Türkiye)

About this study

Official title: Comparison Of The Effects Of Melatonin Premedication And Ketamine On Postoperative Sleep Quality İn Rhinoplasty: A Prospective Randomized Controlled Study

Background Postoperative sleep disorders are common complications of surgery and anesthesia that prolong morbidity and hospital stay. Various methods are being explored to prevent and treat these issues. This study was designed to investigate the effects of ketamine, melatonin, and their combination on postoperative sleep disturbances and pain.

Methods Patients were randomly allocated into three groups: melatonin (Group M), ketamine (Group K), and a melatonin-ketamine combination (Group MK). Group M received 0.1 mg/kg oral melatonin preoperatively (60 minutes before surgery) and postoperatively at 21:00; Group K received 0.3 mg/kg IV ketamine during anesthesia induction; and Group MK received both regimens. Sleep quality was assessed on the first postoperative day using the Richards-Campbell Sleep Questionnaire (RCSQ), and pain intensity was evaluated with the Numeric Rating Scale (NRS). Early extubation-related complications (e.g., coughing, breath-holding, desaturation, vomiting, and laryngospasm) and delayed complications in the post-anesthesia care unit (PACU) were documented. Demographic variables, including ASA physical status scores, were recorded. Intraoperative monitoring comprised basal, post-intubation, and post-extubation measurements of heart rate (HR), systolic arterial pressure (SAP), diastolic arterial pressure (DAP), and mean arterial pressure (MAP) at 30-minute intervals, together with recording surgery and extubation durations.

Read the detailed description

Participants Patients aged 18-65 years with an ASA score of I-II were included. Exclusion criteria were body mass index (BMI) ≥ 30 kg/m², obstructive sleep apnea syndrome (OSAS), psychiatric disorders, renal failure, liver failure, cardiovascular disease, malignancy, pregnancy, or allergies to melatonin or ketamine. Randomization (1:1:1) was achieved via sealed opaque envelopes.

Interventions Patients were premedicated in the preoperative holding area 60 minutes before induction with intravenous midazolam (0.01 mg/kg), and subjects in Groups M and MK additionally received oral melatonin (0.1 mg/kg). After premedication, each patient was transferred to the operating theater, where continuous electrocardiography, pulse oximetry, noninvasive arterial pressure monitoring, and neuromuscular transmission (NMT) monitoring were applied. Anesthesia was induced with intravenous propofol (2 mg/kg), lidocaine (1 mg/kg), and rocuronium (0.6 mg/kg); at this point, patients in Groups K and MK received a supplemental ketamine bolus (0.3 mg/kg). Following confirmation of full neuromuscular blockade (train-of-four ratio = 0 %) and adequate hypnotic depth, endotracheal intubation was performed. Anesthesia was maintained with sevoflurane (0.5-1.0 minimum alveolar concentration [MAC] at a fresh gas flow of 1 L/min) and a remifentanil infusion (0.1-0.3 µg/kg/min). Dosages were titrated to maintain heart rate and systolic arterial pressure within 20-30 % of baseline values, ensuring mean arterial pressure did not fall below 50 mmHg.

Hemodynamic variables-including heart rate, systolic and diastolic arterial pressures, and mean arterial pressure-were recorded at four predefined time points: baseline (pre-induction), immediately post-intubation, at 30-minute intervals intraoperatively, and post-extubation. Thirty minutes before the end of surgery, postoperative analgesia was initiated with tramadol (2 mg/kg) and paracetamol (10 mg/kg) administered as slow intravenous boluses; ondansetron (0.1 mg/kg IV) was given prophylactically for nausea. Neuromuscular blockade was reversed, if necessary, with sugammadex to achieve a train-of-four ratio ≥ 90 %, and patients were extubated once adequate spontaneous ventilation and consciousness had returned. The extubation interval (time from anesthetic discontinuation to return of consciousness) and total surgical duration were documented. In the post-anesthesia care unit (PACU), nausea, vomiting, and pain scores were assessed; patients with moderate to severe nausea or vomiting received an additional 0.1 mg/kg ondansetron IV, and those reporting a resting numerical rating scale (NRS) pain score > 4 were given meperidine (0.5 mg/kg IV) as rescue analgesia. Finally, at 21:00 on postoperative day 1, Groups M and MK received a second oral dose of melatonin (0.1 mg/kg), and sleep quality and pain were re-evaluated at the bedside.

Outcomes Sleep quality was evaluated on the night preceding surgery and on the first postoperative night using the Richards-Campbell Sleep Questionnaire (RCSQ), which exhibits high internal consistency (Cronbach's α = 0.82) and correlates moderately with polysomnography. The RCSQ comprises five domains-sleep depth, sleep latency, number of awakenings, sleep efficiency, and overall sleep quality-each rated on a 0-100 mm visual analog scale, with higher scores indicating better sleep. Postoperative pain intensity was measured in the post-anesthesia care unit (PACU) and at 24 hours after surgery using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain).

Postoperative complications were recorded prospectively as follows: cough severity was graded by the Cough Severity Score (0 = none; 1 = mild; 2 = moderate; 3 = severe; 4 = very severe); apnea was defined as absence of a respiratory waveform for ≥ 10 seconds on capnography; desaturation was identified when SpO₂ fell below 90 % on continuous pulse oximetry; laryngospasm was classified according to the Laryngospasm Severity Scale (grade 1 = mild retraction; grade 2 = intercostal retractions; grade 3 = complete airway obstruction); and vomiting was quantified using the Rhodes Index of Nausea, Vomiting, and Retching (INVR). Finally, the Aldrete score was documented immediately before PACU discharge, and the interval from PACU admission to attainment of the discharge criterion was recorded.

Statistical Analysis Statistical analyses were performed using IBM SPSS Statistics v23.0 (IBM Corp., Armonk, NY, USA). Categorical variables are reported as frequencies and percentages and were compared by Pearson's chi-square or Fisher's exact test, as appropriate. Continuous variables were first assessed for normality using the Shapiro-Wilk test. Variables conforming to a normal distribution are presented as mean ± standard deviation and compared by one-way analysis of variance (ANOVA); homogeneity of variances was verified with Levene's test, and post hoc pairwise comparisons were conducted using Tukey's honestly significant difference or Games-Howell tests, as dictated by variance equality. Non-normally distributed variables are expressed as median (interquartile range) and were analyzed via the Kruskal-Wallis H test followed by Dunn's multiple-comparison test with Bonferroni adjustment. Sample size estimation using G*Power 3.1 (α = 0.05; 1 - β = 0.85; effect size f = 0.25) indicated that 60 patients per group were required. To allow for an anticipated 10% attrition rate, 200 patients were recruited; 17 were subsequently excluded (did not meet inclusion criteria or declined to participate), yielding a final sample of 183 participants.

Being tested
Melatonin (N-acetyl-5-methoxytryptamine), Ketamine
Keywords
Rhinoplasty, Sleep Disorder, Melatonin, Ketamine
Medical subject headings
Sleep Wake Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Melatonin (N-acetyl-5-methoxytryptamine)Drug

    0.1 mg/kg oral melatonin was administered twice

  • KetamineDrug

    0.3 mg/kg intravenous ketamine was administered during anesthesia induction.

Study groups in NCT06898463
Study groupRoleWhat they receive
M GROUPActive comparatorIn Group 1 (Melatonin, M), patients received 0.1 mg/kg oral melatonin 60 minutes before surgery in the premedication room and at 9 PM on the first postoperative day.
Receives: Drug: Melatonin (N-acetyl-5-methoxytryptamine)
K GROUPActive comparatorIn Group 2 (Ketamine, K), patients were administered 0.3 mg/kg intravenous ketamine during anesthesia induction.
Receives: Drug: Ketamine
M-K GROUPActive comparatorIn Group 3 (Melatonin-Ketamine, MK), patients received 0.1 mg/kg oral melatonin in the premedication room 60 minutes before surgery and at 9:00 PM on the first postoperative day, and 0.3 mg/kg intravenous ketamine during anesthesia induction.
Receives: Drug: Melatonin (N-acetyl-5-methoxytryptamine); Drug: Ketamine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To compare the effects of melatonin and ketamine on postoperative sleep disturbances.

    On postoperative day 1, patients' sleep quality was assessed at bedside using the Richards-Campbell Sleep Questionnaire (RCSQ). Although primarily used in intensive care settings, the RCSQ is also valid for assessing sleep in postoperative patients. It shows high internal consistency and moderate correlation with polysomnography. The RCSQ includes five items: sleep depth, latency, awakenings, efficiency, and overall quality. Each item is rated on a 0-100 mm visual analog scale, where higher scores reflect better sleep. The total score is the average of the five items.

    Measured: From enrollment to the end of treatment at 21 Mounths

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2025
  2. Study start19 Sep 2022
  3. Primary completion25 May 2024
  4. Study completion25 Dec 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Factorial
Masking
Double blind
Who is masked
Care provider, Investigator
Enrolment
183 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06898463
Sponsor's protocol ID
2022/927
Status last verified
Apr 2025
First submitted
12 Mar 2025
Last updated
9 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Share the abstract and materials and methods section

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Melatonin (N-acetyl-5-methoxytryptamine) and Ketamine in people with Postoperative Sleep Disturbances, run by Konya City Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To compare the effects of melatonin and ketamine on postoperative sleep disturbances. (time frame: From enrollment to the end of treatment at 21 Mounths). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in